Direct answer
Small trials suggest selected cognitive benefits during cold exposure, sleep loss or demanding tasks, but the review judged evidence insufficient for confident recommendations. These findings do not demonstrate restoration of depleted brain neurotransmitters or establish a routine dose. Depression or ADHD treatment, oral NALT superiority and long-term safety remain unsupported or uncertain.
- Small trials suggest benefits for selected cognitive tasks during cold exposure, sleep loss or demanding laboratory tasks. The 2015 rapid evidence assessment judged the evidence insufficient for confident recommendations (Attipoe et al.).
- Tyrosine is a catecholamine precursor. Stress-related catecholamine depletion is a mechanistic rationale, largely drawn from animal work; a benefit in a human cognitive task does not prove that depletion was measured or corrected (Young).
- Routine depression or ADHD treatment is not supported. The ADHD evidence consists of small, older adult and child trials (Reimherr et al.; Nemzer et al.). The cited Cochrane review concerns phenylketonuria, not ADHD.
- Some acute experiments used 100–150 mg/kg; 150 mg/kg equals 10.5 g for a 70 kg person. Timing and dose differed across studies. These research protocols do not establish a routine self-treatment dose or long-term safety (cold-exposure trial; VKM risk assessment).
- Medication review is needed with MAOIs, levodopa, thyroid treatment or stimulants. The cited MAOI review documents tyramine and drug interactions; it does not establish that L-tyrosine supplements cause hypertensive crises. Thyroid and stimulant concerns also require distinction between mechanism and clinical interaction evidence.
- Evidence grade: Moderate
Table of Contents
- Evidence summary
- What it is
- All forms and types of L-tyrosine
- How it works
- What works and what doesn't
- Benefits with evidence grades
- Risks and side effects
- Interactions and evidence limits
- Who should avoid it
- Dosage and how to take it
- Infographics and text equivalents
- Frequently asked questions
- Sources
Evidence Summary
Evidence grades below are editorial judgments, not formal GRADE ratings. Most studies are small and short. A review’s declared support does not establish the financial independence of every included trial, and undisclosed purchase or donation terms remain unknown.
| Claim | Evidence | Source country | Funding / conflict tracing | Strength |
|---|---|---|---|---|
| Acute-stress cognition | Human trials and reviews suggest benefit mainly during cold, sleep deprivation, operational stress, or very demanding tasks. | USA military trials; Netherlands trials; Canadian essay and US review | Many early studies originated in US military or Dutch military-linked settings; a 2015 Military Medicine review was supported by the Defense Health Program and USUHS Human Performance Resource Center. Military or academic affiliation alone does not resolve each trial’s funding or conflicts. | Moderate |
| Working memory | Small placebo-controlled studies show benefit in difficult N-back or cold-stress tasks, but older-adult dose-response work found worse high-load working memory at higher doses. | Netherlands, USA | N-back study: NWO grant and no commercial conflicts declared; methods name Bulkpowders tyrosine and Sigma-Aldrich placebo, without purchase/donation terms. Older-adult dose-response study: EFRO, Dutch provincial and NWO support, no conflicts declared, and Bulkpowders tyrosine mixed with Arla yoghurt. | Mixed-to-moderate |
| Physical performance / exercise | Heat and sport studies are inconsistent; multiple trials found no performance benefit. | UK, USA, Türkiye-linked authorship | 2025 soccer study reported no specific funding and no competing interests; one caffeine-theanine-tyrosine athlete trial was funded and supplied by Nature’s Bounty and had current or former company-employed authors. It cannot isolate tyrosine and is excluded from the independent efficacy basis. | Weak / mixed |
| ADHD | One open adult ADD trial showed initial response but tolerance by week 6; one small single-blind child ADDH trial found no significant improvement. | USA | Funding not disclosed in PubMed records; evidence is old, small, and not robustly blinded. | Insufficient |
| Depression | A 65-person double-blind trial found no antidepressant activity versus placebo. | USA | Funding not disclosed in PubMed abstract; trial design is stronger than open reports and weighs against benefit. | Doesn't work for routine depression |
| PKU supplementation | Cochrane review found higher blood tyrosine but no significant clinical outcome differences across included trials. | UK / international review | Cochrane methods; review included three suitable trials with 56 people and judged evidence too small for routine recommendation. | Biochemical effect; insufficient clinical benefit |
| Form choice | Free-form L-tyrosine has the best human oral evidence; NALT is more soluble but poorly converted in human IV studies; tyrosine ethyl ester lacks human supplement evidence. | USA/Europe mixed | The NALT abstract does not report funding or conflicts; its intravenous findings do not establish an oral head-to-head comparison. The Nature’s Bounty mixed-ingredient trial cannot isolate tyrosine efficacy. | Human oral evidence for L-tyrosine; oral comparative advantage unproven |
What it is
L-tyrosine is a conditionally essential aromatic amino acid made from phenylalanine and obtained from protein-rich foods such as dairy, meat, fish, eggs, seeds, nuts, and beans (Nutrients). In supplement form, it is usually sold as free-form L-tyrosine powder or capsules, or as N-acetyl-L-tyrosine (NALT), a more water-soluble acetylated derivative (PubMed).The active compound(s) — what actually does the work
The relevant active compound for most nootropic claims is free L-tyrosine, because it raises plasma tyrosine and can increase the tyrosine-to-other-large-neutral-amino-acids ratio that favors transport toward the brain (Nutrients). NALT must be deacetylated into free tyrosine before it can act as tyrosine, and a human infusion study found only a 25% plasma tyrosine increase while 56% of the infused NALT was excreted in urine within four hours (PubMed). The cited studies do not establish efficacy, safety or superior bioavailability for oral tyrosine ethyl ester. > Primary-source quote: In the NALT human infusion study, the authors concluded that “the usefulness of NAT and NAC as precursors for the corresponding amino acids in humans is not apparent” (PubMed).All forms and grades
| Form | What it is | Bioavailability evidence | Best use | Evidence limits | Verdict |
|---|---|---|---|---|---|
| Free-form L-tyrosine | The standard amino-acid form used in most stress and cognition trials. | Human studies show plasma increases. The older-adult dose study measured responses to 100, 150 and 200 mg/kg; its sampling times do not establish universal peak timing. | Experimental acute stress or laboratory cognition protocols; no routine nootropic regimen established. | Small, short trials do not establish routine long-term use. | Best-studied form. |
| N-acetyl-L-tyrosine (NALT; acetyl-L-tyrosine) | Acetylated tyrosine derivative with better water solubility. | Human IV data show poor conversion: 5 g IV NALT raised plasma tyrosine only 25% and 56% was excreted in urine. | Studied as an intravenous amino-acid precursor; oral nootropic efficacy unestablished. | The human precursor study used intravenous infusion; oral absorption and conversion need their own evidence. | More soluble; oral superiority unproven. |
| Tyrosine ethyl ester | Esterified tyrosine form sometimes discussed as a prodrug-style form. | None of the cited human studies tests oral tyrosine ethyl ester. Findings about methyl ester or other derivatives cannot establish ethyl-ester efficacy. | Research chemistry, not routine supplementation. | No oral human efficacy or safety claim is established by the cited evidence. | Insufficient evidence. |
How it works
What the body does with it
Tyrosine sits at a biochemical crossroads: it can be used for protein synthesis, converted into catecholamines, incorporated into thyroid hormone chemistry, and used in melanogenesis. NCBI Bookshelf describes catecholamines—dopamine, norepinephrine, and epinephrine—as derived from tyrosine through tyrosine hydroxylase converting tyrosine to L-DOPA, followed by conversion to dopamine and onward to norepinephrine and epinephrine (NCBI Bookshelf). PubChem's tyrosine metabolism pathway also lists tyrosine as a source for L-DOPA, dopamine, adrenaline, noradrenaline, thyroxine, triiodothyronine, and melanin (PubChem PathBank).Why form and delivery matter
Brain uptake depends less on total tyrosine alone and more on the ratio of tyrosine to competing large neutral amino acids, which is why many trials dose tyrosine after fasting and avoid co-ingestion with high-protein meals (eNeuro). This is also why taking tyrosine inside a protein-heavy pre-workout or meal may not reproduce fasting research effects. > Primary-source quote: “Tyrosine is the precursor of the catecholamines, converted to dopamine via L-Dopa,” the eNeuro older-adult trial notes when explaining its mechanistic rationale (eNeuro).What works and what doesn't
| Claimed benefit | Verdict | Evidence grade | Key evidence | Key caveat |
|---|---|---|---|---|
| Cognitive performance under acute stress: cold, sleep deprivation, military stress | MAY HELP selected stress-specific tasks | Moderate | Cold-stress and sleep-loss studies show working-memory or vigilance protection; Military Medicine review says evidence is insufficient for confident recommendations but promising for cognition. | Mostly acute, high-dose, small, often military-relevant studies; not everyday stress. |
| Working memory in healthy adults | MIXED | Low-to-moderate | 2 g L-tyrosine improved demanding 2-back performance in young adults; higher doses worsened high-load working memory in older adults. | Baseline dopamine function, age, dose, task difficulty, and fasting state likely matter. |
| Physical performance / exercise | MIXED / mostly DOESN'T | Low | Load-carriage heat study found 150 mg/kg did not influence cognitive or exercise outcomes; 2025 soccer heat study found no physical or decision-making benefit. | Some older heat/cycling findings are positive, but replication is weak. |
| ADHD | INSUFFICIENT EVIDENCE | Very low | Open adult ADD trial showed tolerance by 6 weeks; small single-blind child study found no significant improvement. | Not a substitute for ADHD medication; evidence is old and underpowered. |
| Depression | DOESN'T for routine major depression | Low-to-moderate | 65-person double-blind trial found no antidepressant activity. | Dopamine-dependent depression subgroup claims remain unproven and not generalizable. |
| Stress resilience / feeling less stressed | MIXED | Low | Evidence supports cognitive preservation under physical/operational stress more than subjective calm. | A severe-stress study found tyrosine increased anger and did not improve most subjective or physiological stress responses. |
| Phenylketonuria (PKU) supplementation | INSUFFICIENT EVIDENCE for routine extra supplementation beyond specialist diet | Moderate for biochemical increase; low for clinical outcomes | Cochrane: blood tyrosine increased, but no significant differences in other outcomes. | PKU care is medical nutrition therapy; do not self-supplement outside a metabolic clinic. |
Benefits by claim
Acute-stress cognition: evidence grade B-
Cold-stress evidence is the cleanest mechanistic story. In one eight-man Naval Medical Research Institute study, 150 mg/kg L-tyrosine given two hours before cold exposure improved delayed matching-to-sample accuracy at the longest delay interval affected by cold, while tyrosine at 22°C had no effect (PubMed). A sleep-loss study found that 150 mg/kg L-tyrosine in a split dose reduced the usual decline on a psychomotor task and reduced lapse probability on a high-event-rate vigilance task for roughly three hours (PubMed).Working memory and executive control: evidence grade C+
A crossover N-back study in 22 female undergraduate students reported that 2 g L-tyrosine improved accuracy in the demanding 2-back but not easier 1-back condition, with no significant changes in heart rate, blood pressure, or mood (Frontiers in Behavioral Neuroscience). The same result should not be generalized to all ages: in a double-blind randomized crossover dose-comparison trial of older adults, without a placebo condition, 100, 150, and 200 mg/kg produced dose-dependent plasma increases, but higher dose-response was associated with worse high-load working memory (Nutrients).Physical performance and exercise: evidence grade C-/D
A conference abstract reporting a military-style load-carriage study in 40°C heat concluded that 150 mg/kg L-tyrosine did not influence cognitive function or steady-state exercise or time-trial outcomes after carrying 25 kg (Journal of the International Society of Sports Nutrition). A 2025 soccer-player heat study found no effect of 150 mg/kg L-tyrosine on power output, decision-making, cognitive appraisal, or affective valence during a 92-minute high-intensity intermittent cycling sprint protocol (PLOS One).ADHD: evidence grade D
The adult ADD signal is weak and short-lived: an open eight-week trial in 12 adults found eight initial responders, but all responders developed tolerance by week six, and the authors concluded L-tyrosine was not useful for residual-type ADD (PubMed). A seven-child single-blind ADDH study found no significant improvement with oral tyrosine (PubMed).Depression: evidence grade D
A randomized double-blind trial of 65 outpatients with major depression compared L-tyrosine 100 mg/kg/day, imipramine 2.5 mg/kg/day, and placebo for four weeks and found no evidence that tyrosine had antidepressant activity (PubMed). A later mood review stated that the evidence for tyrosine loading as a depression treatment is “even less promising” than tryptophan loading and that the only randomized double-blind tyrosine trial did not show antidepressant benefit (PubMed).PKU supplementation: evidence grade C
Cochrane's 2021 update included three suitable trials with 56 people, found significantly higher blood tyrosine with supplementation, but found no significant differences in other outcomes and no evidence to routinely add tyrosine in PKU (Cochrane). This does not mean tyrosine is irrelevant in PKU diets; it means extra standalone supplementation should be managed by a metabolic specialist rather than marketed as a cognitive fix.Risks and side effects
| Side effect or concern | Frequency | Dose relationship | What to watch for | Evidence note |
|---|---|---|---|---|
| Gastrointestinal symptoms or headache | Not established | No reliable dose–frequency relationship established | Some participants were excluded after vomiting or headache in the small older-adult experiment; that does not establish causation or incidence. | The current WebMD summary says common side effects are not well known. (WebMD; older-adult study) |
| Anger or other mood concerns | General incidence unknown | Not established across doses or routine use | A military severe-stress experiment found increased anger at a total 300 mg/kg; this does not establish routine anxiety or insomnia rates. | Specific experimental finding; other subjective and physiological responses were largely unchanged. (severe-stress study) |
| Blood pressure / pulse concerns | No reliable incidence estimate | Direct supplement interaction severity unquantified | The small N-back trial found no blood-pressure or heart-rate effect; that cannot rule out risk in other populations. | MAOI drug and tyramine interactions should not be attributed to L-tyrosine without direct evidence. (N-back trial; MAOI review) |
| Thyroid measures / treatment concerns | Clinical adverse-event incidence unknown | Routine supplement dose–risk relationship unestablished | A seasonal Antarctic trial using 12 g daily reported lower TSH and higher free T3 in winter. | It did not test coadministration with thyroid medication or establish a clinical interaction. (Antarctic trial) |
| Melanin / pigmentation pathway interactions | Clinical frequency unknown | Not established for oral supplement doses | Do not expect a proven tanning benefit; discuss use with the treating team for melanoma or pigment disorders. | Experimental melanocyte models show substrate/regulatory effects, not clinical harm from oral supplement doses. (Slominski mechanistic review) |
| Severe allergic reaction | Frequency unknown | Not established | Breathing difficulty or swelling of the mouth, tongue or throat requires urgent medical help. | The clinical summary lists this possibility without a frequency estimate. (WebMD) |
Interactions and evidence limits
| Interacts with | Examples | Severity | Mechanism | Action |
|---|---|---|---|---|
| MAOIs | Phenelzine, tranylcypromine, isocarboxazid, selegiline, rasagiline, linezolid (MAOI-like antibiotic) | Prescriber review; direct tyrosine risk unquantified | MAOIs have serious interactions with tyramine and some medicines. L-tyrosine is a different compound; the cited review does not establish a tyrosine-induced hypertensive-crisis risk. | Avoid self-combination; urgent care for severe headache, chest pain, very high BP, confusion, or neurologic symptoms. |
| Levodopa / Parkinson's medication | Levodopa-carbidopa, levodopa-benserazide, mucuna pruriens/L-DOPA supplements | Transport competition; direct supplement severity unquantified | Tyrosine and levodopa are aromatic/large neutral amino-acid pathway competitors at gut and blood-brain transport steps. | Do not start without Parkinson's clinician approval; separate dosing if prescriber permits. |
| Thyroid medication | Levothyroxine, liothyronine, desiccated thyroid; antithyroid drugs such as carbimazole or propylthiouracil | Possible interaction; clinical evidence incomplete | Tyrosine participates in thyroid hormone synthesis; added precursor may theoretically alter thyroid hormone balance or medication response. | Avoid in hyperthyroidism/Graves'; discuss with clinician and monitor TSH/T3/T4 if used. |
| Stimulant medicines | Adderall/amphetamine salts, lisdexamfetamine, methylphenidate, modafinil/armodafinil | Caution; direct interaction data limited | Additive alerting or cardiovascular effects are mechanistically plausible; a clinical tyrosine–stimulant interaction is not established by the cited sources. | Do not stack casually; monitor BP, pulse, anxiety, and sleep. |
| Caffeine | Coffee, energy drinks, pre-workouts, caffeine pills | Caution | Caffeine is an adenosine antagonist and can increase alertness, jitteriness, and cardiovascular strain; combined stimulant load may worsen anxiety or insomnia. | Keep caffeine low when testing tyrosine; avoid late-day use. |
| Other catecholamine-increasing supplements | Yohimbine, synephrine/bitter orange, ephedra/ephedrine, pseudoephedrine, phenylephrine, high-dose green tea extract, rhodiola in sensitive users, mucuna/L-DOPA, phenylalanine | Direct tyrosine combination risks unestablished here | Additive sympathomimetic or dopamine/norepinephrine pathway effects; decongestants and ephedrine-like compounds have blood-pressure risk. | Avoid aggressive “focus” stacks; never combine with MAOIs. |
| Antidepressants and psychiatric medicines | SNRIs, bupropion, TCAs, antipsychotics, MAOIs, ADHD meds | Prescriber review; direct tyrosine interactions uncertain | Potential overlap with dopamine/norepinephrine tone, BP, anxiety, agitation, or sleep. | Use only with prescriber knowledge if you take psychiatric medication. |
The levodopa review acknowledges University of Florida and Lauren and Lee Fixel Family Foundation support. Author C. Rusch discloses later employment at Abbott Nutrition, while stating that the work was completed at the university; the other authors declare no competing interests. The severe-stress trial reports US Army Medical Research and Materiel Command support and no conflicts. These declarations do not establish the independence of every cited underlying study (levodopa review; severe-stress trial).
Who should avoid it
Ask the treating clinician before adding a tyrosine supplement if you use MAOIs, levodopa, thyroid treatment or stimulants. The sources reviewed do not establish safety for pregnancy, breastfeeding or complex medical conditions, or demonstrate all the proposed drug interactions. PKU supplementation belongs within specialist medical nutrition care. Mechanistic melanocyte research does not establish a clinical melanoma contraindication.A severe psychological-stress study in healthy service members found that tyrosine increased anger but did not change most subjective or physiological stress responses, which is a practical caution for anxiety-prone users (Neuropsychobiology). Tyrosine and L-DOPA regulate melanogenesis in experimental models; this review does not establish melanoma harm from oral supplements or a clinical tanning benefit. People receiving melanoma treatment should discuss supplements with their treating team (Pigment Cell & Melanoma Research).
Dosage and how to take it
| Use case | Studied dose range | Clinical interpretation | Timing | Notes |
|---|---|---|---|---|
| Acute cold / sleep-loss / operational stress | Often 100–150 mg/kg; some studies used up to 20 g or split doses. | Experimental protocol; not an established self-treatment regimen. | Varied by study; cold trial dosed two hours before exposure, and sleep-loss trial used split doses. | High research doses are not routine daily supplement doses. |
| General nootropic trial in healthy adult | 2 g improved demanding N-back in one young-adult study. | No routine nootropic dose with established benefit and long-term safety. | The N-back study tested one hour after dosing and controlled food intake. | Stop if anxious, jittery, or sleep worsens. |
| Exercise / pre-workout | Often 150 mg/kg in heat studies. | Not recommended as a core ergogenic aid. | Timing varied by protocol; routine pre-workout use unestablished. | Evidence is mixed and often negative. |
| PKU | 100 mg/kg/day in some trials. | Only under metabolic clinic supervision. | Per medical nutrition plan. | Cochrane does not support routine extra supplementation for clinical outcomes. |
| NALT | 5 g IV in human precursor study. | IV findings cannot establish an oral form recommendation. | Not applicable. | Oral head-to-head bioavailability and clinical benefit remain unestablished here. |
Infographics and text equivalents
Infographic 1: Tyrosine pathway map
| L-tyrosine: the biochemical crossroads | |
|---|---|
| L-tyrosine | |
| Catecholamines | L-DOPA → dopamine → norepinephrine → epinephrine |
| Thyroid hormones | Tyrosine residues+ iodine → T3/T4 |
| Melanin | Tyrosinase pathway → L-DOPA / dopaquinone |
Text version of this infographic
L-tyrosine is a precursor for three major pathways: catecholamines, thyroid hormones, and melanin. In the catecholamine pathway, L-tyrosine is converted to L-DOPA, then dopamine, then norepinephrine, then epinephrine. In thyroid hormone synthesis, tyrosine residues in thyroglobulin are iodinated and coupled to form T3 and T4. In melanogenesis, tyrosine enters the tyrosinase pathway to form L-DOPA, dopaquinone, and melanin pigment.
Infographic 2: Acute-stress cognitive benefit window
The expected usefulness of L-tyrosine is lowest during normal daily demand, rises during cold exposure, sleep loss, and military-style operational stress, and falls again when used casually for routine daily focus. The best evidence signal is acute stress combined with an otherwise intact catecholamine system.
Infographic 3: Evidence strength by claim
| Claim | Evidence strength |
|---|---|
| Acute stress cognition | Moderate |
| Working memory | Mixed |
| Exercise performance | Weak |
| ADHD | Insufficient |
| Depression | Negative |
| PKU routine add-on | Biochemical increase only; insufficient clinical outcome evidence |
Infographic 4: Dosing decision guide
| Study doses are not treatment recommendations | Small, short trials |
| 2 g in one N-back experiment | 22 young women |
| Long-term safety uncertain | No routine dose established |
| Research dose | 100–150 mg/kg |
| Acute stress only | 60–120 min before |
| Not daily routine | Avoid / ask doctor |
| MAOI / levodopa | Thyroid meds |
| Stimulants | Hyperthyroid / anxiety |
Text version of this infographic
One small N-back experiment used 2 g in 22 young women. Some stress experiments used 100–150 mg/kg with protocol-specific timing. These doses do not establish a routine self-treatment schedule or long-term safety. Avoid or ask a doctor first if using MAOIs, levodopa, thyroid medication, prescription stimulants, or if you have hyperthyroidism or significant anxiety.
Infographic 5: Interaction matrix
| Interaction | Severity | Reason |
|---|---|---|
| MAOIs | Prescriber review | Direct tyrosine interaction severity is unproven; do not confuse it with established tyramine or drug interactions. |
| Levodopa | Moderate to serious | Transport competition may reduce Parkinson's medication effect. |
| Thyroid medication | Moderate | Precursor overlap; monitor TSH/T3/T4. |
| Stimulants and caffeine | Caution to moderate | Additive jitteriness, anxiety, pulse, and sleep disruption. |
| Other catecholamine stacks | Caution | Yohimbine, synephrine, decongestants, and mucuna may add sympathetic or dopamine-pathway effects. |
Infographic 6: NALT vs L-tyrosine
| Feature | Free-form L-tyrosine | NALT |
|---|---|---|
| Solubility | Lower | Higher |
| Human evidence | Used in most cognition/stress trials | Human IV precursor data show poor conversion |
| Plasma tyrosine effect | Dose-dependent increase | 5 g IV raised plasma tyrosine only 25% in one study |
| Waste/excretion signal | Not the main concern | 56% excreted unchanged in urine after 5 g IV in one human study |
| Verdict | Preferred | Oral superiority unproven |
Related research
For deeper, evidence-graded context on the conditions L-tyrosine is most often used for, see Pure City Research's condition guides: - Stress, anxiety & depression: prevention and management guideFrequently Asked Questions
Does L-tyrosine increase dopamine?
L-tyrosine is the biochemical precursor to L-DOPA and dopamine, but taking more tyrosine does not guarantee a simple or linear dopamine boost in daily life. Evidence is strongest when catecholamine demand is high, such as cold stress or sleep deprivation, rather than when a rested person wants extra motivation (NCBI Bookshelf, Journal of Psychiatry & Neuroscience).Is L-tyrosine good for studying or exams?
It may help demanding working-memory tasks under acute stress, but the evidence does not support using it as a universal study pill. A 2 g study improved 2-back performance in young adults, while older-adult high-dose work found possible cognitive worsening at higher doses (Frontiers in Behavioral Neuroscience, Nutrients).Is NALT better than L-tyrosine?
The cited research does not demonstrate oral NALT superiority. A human IV study found 56% urinary excretion and a 25% plasma tyrosine increase after 5 g; those findings cannot by themselves establish an oral comparison. Free-form L-tyrosine is the form used in the cited human oral cognition trials (PubMed).Can I take L-tyrosine with Adderall or caffeine?
People taking Adderall or other stimulants, or using high caffeine, should discuss L-tyrosine with their prescriber, particularly with anxiety, insomnia, hypertension or palpitations. Additive catecholamine effects are a mechanism-based concern; the cited physiology and MAOI reviews do not demonstrate a clinical tyrosine–Adderall interaction (NCBI Bookshelf, Health Psychology Research).
Can L-tyrosine help ADHD?
Current evidence is insufficient. One open adult ADD study found early response but tolerance by week six, and a small single-blind child ADDH study found no significant improvement (PubMed, PubMed).Can L-tyrosine help depression?
Routine use for depression is not supported. A 65-person double-blind trial found no evidence of antidepressant activity for 100 mg/kg/day L-tyrosine over four weeks (PubMed).Is L-tyrosine safe with thyroid medication?
Involve the clinician managing your thyroid medication. WebMD lists thyroid medicines as requiring discussion and says interaction evidence is incomplete. The Antarctic trial reported thyroid-marker changes during 12 g daily supplementation but did not test a tyrosine–thyroid-drug combination (WebMD, PubMed).Is L-tyrosine permitted as a supplement
Permission to sell a supplement, its permitted dose and its allowed claims depend on the country and product. The historical Indian document cited below does not establish current worldwide legality or approval of a particular product. Check the applicable regulator and product label; supplement status is not evidence of clinical efficacy or long-term safety.
Sources
- Young SN. L-Tyrosine to alleviate the effects of stress? Journal of Psychiatry & Neuroscience. 2007. PMC
- Attipoe S, Zeno SA, Lee C, et al. Tyrosine for Mitigating Stress and Enhancing Performance in Healthy Adult Humans, a Rapid Evidence Assessment of the Literature. Military Medicine. 2015. Oxford Academic
- Shurtleff D, Thomas JR, Schrot J, Kowalski K, Harford R. Tyrosine reverses a cold-induced working memory deficit in humans. Pharmacology Biochemistry and Behavior. 1994. PubMed
- Neri DF, Wiegmann D, Stanny RR, Shappell SA, McCardie A, McKay DL. The effects of tyrosine on cognitive performance during extended wakefulness. Aviation, Space, and Environmental Medicine. 1995. PubMed
- Deijen JB, Wientjes CJ, Vullinghs HF, Cloin PA, Langefeld JJ. Tyrosine improves cognitive performance and reduces blood pressure in cadets after one week of a combat training course. Brain Research Bulletin. 1999. PubMed
- Owasoyo JO, Neri DF, Lamberth JG. Tyrosine and its potential use as a countermeasure to performance decrement in military sustained operations. 1992. Research record
- Lieberman HR. Nutrition, brain function and cognitive performance. Appetite. 2003. PubMed
- ClinicalTrials.gov. Effect of Tyrosine Supplementation on Cognitive Performance and Mood During Military Stress. NCT01913925; United States Army Research Institute of Environmental Medicine sponsor, 80 enrolled, completed in 2009. First registered in 2013; no results posted. A registration is not efficacy evidence. ClinicalTrials.gov
- Colzato LS, Jongkees BJ, Sellaro R, Hommel B. Working Memory Reloaded: Tyrosine Repletes Updating in the N-Back Task. Frontiers in Behavioral Neuroscience. 2013. PMC
- van de Rest O, Bloemendaal M, de Heus R, Aarts E. Dose-Dependent Effects of Oral Tyrosine Administration on Plasma Tyrosine Levels and Cognition in Aging. Nutrients. 2017. PMC
- Bloemendaal M, Zandbelt BB, Wegman J, et al. Neuro-Cognitive Effects of Acute Tyrosine Administration on Reactive and Proactive Response Inhibition in Healthy Older Adults. eNeuro. 2018. PMC
- Coull N, Foster J, Chrismas B, Taylor L. Effect of tyrosine ingestion on cognitive function and load carriage performance in the heat 2015. Research record
- Donnan KJ, Williams EL, Stanger N. Tyrosine supplementation is ineffective in facilitating soccer players' physical and cognitive performance during high-intensity intermittent exercise in hot conditions. PLOS One. 2025. PMC
- Zaragoza J, Tinsley G, Urbina S, Villa K, Santos E, Juaneza A, Tinnin M, Davidson C, Mitmesser S, Zhang Z, Taylor L. Effects of acute caffeine, theanine and tyrosine supplementation on mental and physical performance in athletes. 2019. Research record
- Reimherr FW, Wender PH, Wood DR, Ward M. An open trial of L-tyrosine in the treatment of attention deficit disorder, residual type. American Journal of Psychiatry. 1987. PubMed
- Nemzer E, Arnold LE, Votolato NA, McConnell H. Effect of tyrosine on attention deficit disorder with hyperactivity. Journal of Clinical Psychiatry. 1988. PubMed
- Gelenberg AJ, Gibson CJ, Wojcik JD. Tyrosine for depression: a double-blind trial. Journal of Affective Disorders. 1990. PubMed
- Parker G, Brotchie H. Mood effects of the amino acids tryptophan and tyrosine. Acta Psychiatrica Scandinavica. 2011. PubMed
- Remmington T, Smith S. Tyrosine supplementation for phenylketonuria. Cochrane Database of Systematic Reviews. 2021. Cochrane
- Smith ML, Hanley WB, Clarke JTR, et al. Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria. Archives of Disease in Childhood. 1998. PMC
- Magnusson I, et al. N-acetyl-L-tyrosine and N-acetyl-L-cysteine as tyrosine and cysteine precursors during intravenous infusion in humans. PubMed
- Topall G, Laborit H. Brain tyrosine increases after treating with prodrugs: comparison with tyrosine. 1989. Research record
- Khalil B, et al. Physiology, Catecholamines. StatPearls / NCBI Bookshelf. NCBI Bookshelf
- Schlessinger D, Rahimi N, Schlessinger J. Biochemistry, Melanin. StatPearls / NCBI Bookshelf. NCBI Bookshelf
- PubChem PathBank. Tyrosine Metabolism Pathway. PubChem
- Slominski A, et al. L-tyrosine and L-dihydroxyphenylalanine as hormone-like regulators of melanocyte functions. Pigment Cell & Melanoma Research. 2012;25(1):14–27 (online 2011). PMC
- Edinoff AN, Swinford CR, Odisho AS, Burroughs CR, Stark CW, Raslan WA, Cornett EM, Kaye AM, Kaye AD. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors. 2022. Research record
- Rusch C, Flanagan R, Suh H, Subramanian I. To restrict or not to restrict? Practical considerations for optimizing dietary protein interactions on levodopa absorption in Parkinson's disease. 2023. Research record
- WebMD. Tyrosine: Uses, Side Effects, and More. WebMD
- Norwegian Scientific Committee for Food Safety. Risk assessment of “other substances” – L-tyrosine. VKM
- Food Safety and Standards Authority of India. 2022 direction under Section 16(5): health supplements and nutraceuticals, with annexed regulations. Historical regulatory source; not evidence that a particular product is approved or that these are the latest requirements.
Have a question — or want us to cover something?
Ask about anything on this page, or request the next deep dive: an ingredient, a supplement, or a health concern. We use published research, evidence syntheses, and regulatory guidance, with clear source links.
One daily research roundup
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.
Research funding at a glance
7 disclosure entries. The counts below summarize independence tiers explicitly assigned in this article. They count disclosures, not studies, funding amounts or evidence quality.
Consult this article’s source and funding notes for named funders, countries, relationships and exceptions where available. Institutional backing, researcher interests and trial sponsorship are separate questions. Public funding alone does not establish independence; commercial ties alone do not prove a claim false. This overview is not a new financial audit.
